Sanofi plucks three more NK cell en­gagers from French biotech part­ner, putting down €25M cash

Hav­ing sent one nat­ur­al killer cell en­gager in­to the clin­ic and plot­ted an IND path for a sec­ond, Sanofi is re­turn­ing to a biotech part­ner for more.

This time around, Sanofi wants from In­nate Phar­ma a can­di­date that tar­gets B7H3 — an emerg­ing po­ten­tial check­point in im­muno-on­col­o­gy — as well as op­tions for two more tar­gets. As with its last deal, Sanofi will be re­spon­si­ble for all de­vel­op­ment, man­u­fac­tur­ing and com­mer­cial­iza­tion once In­nate pro­duces the pro­grams.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER